BridgeBio Oncology Therapeutics, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
BridgeBio Oncology announced clinical data for KRAS-targeted programs and a strategic portfolio shift. BBO-8520 (KRAS G12C ON/OFF inhibitor) plus pembrolizumab showed 75% ORR at 500 mg QD in 17 G12C inhibitor-experienced 2L+ NSCLC patients, and 63% ORR (26/41) as monotherapy in treatment-naive patients. The company deprioritized BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer, focusing capital on BBO-8520+pembrolizumab in 2L+ G12C-experienced NSCLC, and BBO-11818/BBO-10203 combinations in KRAS-mutant CRC and PDAC. Cash position: $344.1M as of June 30, 2026, projected to fund operations into 2028.
Why this rating
Positive clinical data and clear focus offset by portfolio narrowing and competitive landscape uncertainty; moderate impact relative to $465M market cap.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.